A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
NCT06037317
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
38
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
SY-3505
Sponsor
Shouyao Holdings (Beijing) Co. LTD